Patents Assigned to Bayer Aktiengesellschaft
  • Publication number: 20240193738
    Abstract: A method of training a prediction tool to generate at least one synthetic full-contrast image from zero-contrast and low-contrast images of a subject may involve receiving a training set a set of images of a set of subjects, the images of each subject comprising a full-contrast image, a low-contrast image, a first zero-contrast image acquired prior to the acquisition of the full-contrast image, and a second zero-contrast image acquired prior to the acquisition of the low-contrast image. An artificial neural network may be trained with the training set by applying the first and second zero-contrast images from the set of images and the low-contrast images from the set of images as input to the artificial neural network and using a cost function to compare the output of the artificial neural network with the full-contrast images from the set of images to train parameters of the artificial neural network using backpropagation.
    Type: Application
    Filed: April 13, 2022
    Publication date: June 13, 2024
    Applicant: Bayer Aktiengesellschaft
    Inventors: Veronica CORONA, Marvin PURTORAB, Sara LORIO, Thiago RAMOS DOS SANTOS
  • Patent number: 12006327
    Abstract: The present invention relates to a novel process for preparing substituted cyclohexane amino acid esters and spiroketal-substituted cyclic keto-enols, and to novel intermediates or starting compounds that are passed through or used in the process according to the invention.
    Type: Grant
    Filed: April 3, 2019
    Date of Patent: June 11, 2024
    Assignee: BAYER AKTIENGESELLSCHAFT
    Inventors: Thomas Himmler, Peter Bruechner, Werner Lindner, Julia Johanna Hahn, Wahed Ahmed Moradi, Reiner Fischer, Michael Dockner
  • Publication number: 20240182452
    Abstract: The present invention provides dihydropyridazinone compounds of general formula (I) in which R1, R2 and R3 are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular of hyperproliferative diseases, as a sole agent or in combination with other active ingredients.
    Type: Application
    Filed: December 28, 2023
    Publication date: June 6, 2024
    Applicants: Bayer Aktiengesellschaft, Bayer Pharma Aktiengesellschaft, The Broad Institute, Inc., Dana-Farber Cancer Institute, Inc.
    Inventors: Manuel ELLERMANN, Stefan Nikolaus GRADL, Charlotte Christine KOPITZ, Martin LANGE, Adrian TERSTEEGEN, Philip LIENAU, Detlev SÜLZLE, Timothy LEWIS, Heidi GREULICH, Xiaoyun WU, Matthew MEYERSON
  • Publication number: 20240185577
    Abstract: The present invention relates to the technical field of machine learning. Subject matter of the present invention is a novel approach for training a neural network and the use of this approach for the processing of (medical) images.
    Type: Application
    Filed: March 24, 2022
    Publication date: June 6, 2024
    Applicant: Bayer Aktiengesellschaft
    Inventors: Matthias LENGA, Marvin PURTORAB, Thiago RAMOS DOS SANTOS, Jens HOOGE, Veronica CORONA
  • Publication number: 20240182431
    Abstract: The present invention relates to a new class of compounds of general formula (I), the Gd3+ chelate complexes thereof, to methods of preparing said compounds, and to the use of said compounds as MRI contrast agents.
    Type: Application
    Filed: March 14, 2022
    Publication date: June 6, 2024
    Applicants: Bayer Aktiengesellschaft, Bayer Aktiengesellschaft
    Inventors: Thomas BRUMBY, Jessica LOHRKE, Simon Anthony HERBERT, Olaf PANKNIN, Thomas FRENZEL, Claudia GREEN, Gregor JOST, Hubertus PIETSCH, Markus BERGER, Sven WITTROCK
  • Patent number: 11998539
    Abstract: The present invention covers aminoquinolone compounds of general formula (I), in which R1, R2, R3, R4, R5, R6, R7, R8 and n are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment and/or prophylaxis of diseases, in particular of diacylglycerol kinase alpha regulated disorders, as a sole agent or in combination with other active ingredients.
    Type: Grant
    Filed: November 30, 2022
    Date of Patent: June 4, 2024
    Assignees: BAYER AKTIENGESELLSCHAFT, BAYER PHARMA AKTIENGESELLSCHAFT, DEUTSCHES KREBSFORSCHUNGSZENTRUM
    Inventors: Norbert Schmees, Lars Wortmann, Dennis Kirchhoff, Thi Thanh Uyen Nguyen, Nicolas Werbeck, Ulf Bömer, Kirstin Petersen, Christina Kober, Christian Lechner, Dirk Kosemund, Rienk Offringa, Mareike Grees, Benjamin Bader
  • Publication number: 20240174683
    Abstract: The present invention relates to Map4K1 inhibitors of formula (I) (I), wherein A, E, G, Q, R1, R2 and R4 have the same meaning as defined in the description, to pharmaceutical compositions and combinations comprising the compounds according to the invention, and to the prophylactic and therapeutic use of the inventive compounds, respectively to the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular for neoplastic disorders, respectively cancer or conditions with dysregulated immune responses or other disorders associated with aberrant MAP4K1 signaling, as a sole agent or in combination with other active ingredients.
    Type: Application
    Filed: February 4, 2022
    Publication date: May 30, 2024
    Applicants: Bayer Aktiengesellschaft, Deutsches Krebsforschungszentrum
    Inventors: Ulrich LÜCKING, Jeffrey Stuart MOWAT, Ludwig ZORN, Lars WORTMANN, Steffen MÜLLER, Gabriele LEDER, Sandra BERNDT, Judith GÜNTHER, Lara KUHNKE, Antje Margret WENGNER, Rafael CARRETERO, Gerd WOHLFAHRT, Anders FRIBERG, Ulf BÖMER, Roland NEUHAUS, Maren OSMERS, Hideki Miyatake ONDOZABAL, Martina SCHÄFER, Louise EAGLING, Julien LEFRANC, Katrin NOWAK-REPPEL, Rienk OFFRINGA, Peng CHEN, Xuewei WANG, Yuanyuan YAN, Kai THEDE, Nikolay SITNIKOV, Berndt BUCHMANN, Dirk KOSEMUND, Detlef STOECKIGT
  • Publication number: 20240156999
    Abstract: The present invention covers compounds of general formula (I): [(C)n-L]-(V)m (I) where C is a chelator and n>1, L is a multi-functional linker moiety comprising multiple functional groups for the covalent attachment of chelator such as a polyamine or polyacid-containing backbone or amino acid containing polymer comprising side-chains with amino, thiol or carboxylic acid moieties such as lysine, cysteine or glutamic acid and V is a tissue targeting moiety where m=1-5 which preferentially coupled through a coupling moiety to either the multifunctional linker moiety L or directly to the chelator moiety C, and stereoisomers, tautomers, N-oxides, hydrates, solvates, and salts thereof, and mixtures of same.
    Type: Application
    Filed: January 31, 2022
    Publication date: May 16, 2024
    Applicants: Bayer Aktiengesellschaft, Bayer AS
    Inventors: Thomas BRUMBY, Alan CUTHBERTSON, Bård INDREVOLL, Waqas RAFIQUE, Vilde Roko KROGSTIE, Véronique CRUCIANI, Alexander KRISTIAN
  • Publication number: 20240150277
    Abstract: The present invention includes compounds of formula (I) and methods for its preparation and treatment of disorders with activated peroxisome preoliferator-activated receptor gamma (PPARG), particularly cancer.
    Type: Application
    Filed: August 31, 2023
    Publication date: May 9, 2024
    Applicants: Bayer Aktiengesellschaft, The Broad Institute, Inc., Dana-Farber Cancer Institute, Inc.
    Inventors: Stephan SIEGEL, Knut EIS, Timo STELLFELD, Léa Aurelie BOUCHÉ, Elisabeth POOK, Joseph Peter BLUCK, Philip LIENAU, Constantia PANTELIDOU, Isabel Sophie JERCHEL-FURAU, Ulf BRÜEGGEMEIER, Sven CHRISTIAN, Detlev SÜLZLE, Anders Roland FRIBERG, Simon HOLTON, Christian LECHNER, Stefan KAULFUSS, Hanna MEYER, Douglas ORSI, Steven James FERRARA, Jonathan GOLDSTEIN, Matthew MEYERSON, Christopher LEMKE
  • Publication number: 20240153163
    Abstract: The present invention relates to the technical field of producing artificial contrast-enhanced radiological images by way of machine learning methods.
    Type: Application
    Filed: November 29, 2021
    Publication date: May 9, 2024
    Applicant: Bayer Aktiengesellschaft
    Inventors: Matthias LENGA, Marvin PURTORAB
  • Patent number: 11975276
    Abstract: Provided are methods for monitoring a filtration and washing operation on a solid-state bulk material in a filter apparatus for cake filtration. The methods include separating a solid-state bulk material in a suspension medium using a filter element for the cake filtration, leading off the suspension medium in the form of a filtrate stream into a filtrate outlet, measuring at least one parameter value of the filtrate stream over a period of time during the filtration and washing operation, and conducting a change analysis of the at least one parameter value over the period of the filtration and washing operation to achieve the end of the filtration and washing operation and/or the effectiveness of the filtration and washing operation.
    Type: Grant
    Filed: April 9, 2019
    Date of Patent: May 7, 2024
    Assignee: BAYER AKTIENGESELLSCHAFT
    Inventors: Kathrin Annette Engelhardt, Reinhard Gross
  • Patent number: 11976334
    Abstract: The present invention covers 2-[(3R)-3-methylmorpholin-4-yl]-4-(1-methyl-1H-pyrazol-5-yl)-8-(1H-pyrazol-5-yl)-1,7-naphthyridine (in the following called “Compound A”), an inhibitor of ATR kinase, for use in a method of treating a hyper-proliferative disease in a subject.
    Type: Grant
    Filed: February 1, 2021
    Date of Patent: May 7, 2024
    Assignees: Bayer Aktiengesellschaft, Bayer Pharma Aktiengesellschaft
    Inventors: Antje Margret Wengner, Gerhard Siemeister, Bernard Händler, Sven Golfier, Andreas Schlicker, Li Liu
  • Publication number: 20240141312
    Abstract: Described herein are novel systems for targeting, editing or manipulating DNA in a cell or cell free environment, using novel type V B-GEn.1 or B-GEn.2 nucleases and variants thereof, as well as methods and kits for manipulating DNA. Further disclosed are novel and improved single guide RNAs.
    Type: Application
    Filed: June 9, 2022
    Publication date: May 2, 2024
    Applicant: Bayer Aktiengesellschaft
    Inventors: Andre COHNEN, Florian RICHTER, Philipp KNYPHAUSEN, Andreas NEERINCX, Saskia Diana MARKERT, Christien BEDNARSKI, Sören TURAN
  • Patent number: 11964953
    Abstract: The present invention covers aminothiazole compounds of general formula (I), in which R1, R2, R3 and R4 are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment and/or prophylaxis of diseases, in particular of diacylglycerol kinase zeta (DGK?) regulated disorders, as a sole agent or in combination with other active ingredients.
    Type: Grant
    Filed: September 14, 2022
    Date of Patent: April 23, 2024
    Assignees: Bayer Aktiengesellschaft, Deutsches Krebsforschungszentrum
    Inventors: Norbert Schmees, Ulrike Roehn, Dennis Kirchhoff, Kirstin Petersen, Mareike Grees, Nicolas Werbeck, Benjamin Bader, Rienk Offringa, Corinna Link
  • Publication number: 20240124522
    Abstract: The present invention relates to novel Mannose-binding lectin (MBL)-associated serine protease (MASP) inhibitory compounds, as well as analogues and derivatives thereof, to processes for the preparation thereof, to the use thereof alone or in combinations for treatment and/or prevention of diseases and to the use thereof for production of medicaments for treatment and/or prevention of diseases, especially for treatment and/or prevention of renal and cardiovascular disorders and of ischemia reperfusion injuries.
    Type: Application
    Filed: April 12, 2023
    Publication date: April 18, 2024
    Applicants: Bayer Aktiengesellschaft, Bayer Pharma Aktiengesellschaft
    Inventors: Donald Bierer, Ingo Flamme, Dmitry Zubov, Thomas Neubauer, Adrian Tersteegen, Cathleen Juhl, Marie Glatz, Jan Dreher, Simon Holton, Carsten Terjung, Lars Baumann, Thorsten Poethko, Jiancheng Xiong, Yibo Qiu
  • Publication number: 20240114882
    Abstract: The invention relates to a method and a system for pesticide management of an arable field, in particular taking into account health-related data of pollinators. The invention also relates to a computer program product and to a storage medium.
    Type: Application
    Filed: October 12, 2020
    Publication date: April 11, 2024
    Applicant: Bayer Aktiengesellschaft
    Inventors: Simon Franz HOFF, Philipp SENGER
  • Patent number: 11952359
    Abstract: The present disclosure relates to substituted thiophene carboxamides and analogues thereof of formula (I) that may be used for protecting plants from bacterial diseases, in particular from bacterial diseases caused by bacteria belonging to the genus Xanthomonas.
    Type: Grant
    Filed: June 30, 2022
    Date of Patent: April 9, 2024
    Assignee: Bayer Aktiengesellschaft
    Inventors: David Bernier, Stéphane Brunet, Jérémy Dufour, Thomas Knobloch, Lionel Nicolas, Tomoki Tsuchiya
  • Patent number: 11951166
    Abstract: The present invention relates to pharmaceutical compositions and combinations comprising regorafenib or its hydrate, solvate, metabolite or pharmaceutically acceptable salt or a polymorph thereof and a PD-1/PD-L1(2) inhibitor for treating, preventing or managing diseases and conditions including hyperproliferative disorders such as cancer in humans and other mammals.
    Type: Grant
    Filed: May 25, 2018
    Date of Patent: April 9, 2024
    Assignee: BAYER AKTIENGESELLSCHAFT
    Inventors: Sabine Hoff, Lars Rose, Dieter Zopf, Fabian Kiessling, Wiltrud Lederle, Dennis Doleschel
  • Publication number: 20240109850
    Abstract: The present invention includes compounds of formula (I) and methods for its preparation and treatment of disorders with activated peroxisome preoliferator-activated receptor gamma (PPARG), particularly cancer.
    Type: Application
    Filed: August 31, 2023
    Publication date: April 4, 2024
    Applicants: Bayer Aktiengesellschaft, The Broad Institute, Inc., Dana-Farber Cancer Institute, Inc.
    Inventors: Knut EIS, Elisabeth POOK, Ulf BRÜGGEMEIER, Adelaide Clara F. A. DE LEMOS, Sven CHRISTIAN, Isabel Sophie JERCHEL-FURAU, Ulrike RAUH, Nico BRÄUER, Timo STELLFELD, Anders Roland FRIBERG, Christian LECHNER, Stefan KAULFUSS, Hanna MEYER, Charlotte Christine KOPITZ, Steven James FERRARA, Jonathan GOLDSTEIN, Matthew MEYERSON, Christopher LEMKE, Timothy A. LEWIS
  • Patent number: 11944690
    Abstract: The present disclosure relates to a liquid pharmaceutical formulation comprising a DOSA-derived tetra-chelate of formula (I), in which M is an ion of a paramagnetic metal, preferably a Gd3+ ion, and R1, R2, R3, R4 and R5 are as defined in the claims, in a pharmaceutical acceptable solvent. The present disclosure also relates to a method of preparation of said liquid pharmaceutical formulation and to a method of imaging involving said liquid pharmaceutical formulation.
    Type: Grant
    Filed: November 21, 2019
    Date of Patent: April 2, 2024
    Assignee: BAYER AKTIENGESELLSCHAFT
    Inventors: Stephan Holzschuh, Thomas Frenzel, Gregor Jost, Jessica Lohrke, Wolfgang Ebert, Thomas Brumby, Wolfgang Halfbrodt